Biomarkeri dislipidemije kod pacijenata sa dijabetesnim stopalom

  • Sanja Vujčić Univerzitet u Beogradu - Farmaceutski fakultet, Katedra za medicinsku biohemiju
  • Tatjana Stefanović Opšta bolnica Acibadem Bel Medic, Biohemijska laboratorija
  • Aleksandra Zeljković Univerzitet u Beogradu - Farmaceutski fakultet, Katedra za medicinsku biohemiju
  • Marija Mihajlović Univerzitet u Beogradu - Farmaceutski fakultet, Katedra za medicinsku biohemiju
  • Jelena Vekić Univerzitet u Beogradu - Farmaceutski fakultet, Katedra za medicinsku biohemiju
DOI: https://doi.org/10.5937/arhfarm72-36296
Ključne reči: lipidni status, male guste LDL čestice, funkcionalnost HDL čestica, dijabetes

Sažetak


Dijabetesno stopalo (DS) je hronična komplikacija dijabetesa koja značajno pogoršava kvalitet života pacijenata i doprinosi visokoj stopi smrtnosti. Noviji podaci ukazuju da i poremećaj metabolizma lipida može biti uključen u razvoj i progresiju DS. Dislipidemija u dijabetesu se odlikuje postojanjem tzv. aterogene trijade, koju čine povišena koncentracija triglicerida (TG), snižena koncentracija HDL-holesterola (HDL-h) i prisustvo malih, gustih LDL čestica. U nedavno sprovedenim studijama utvrđeno je da izražena hipertrigliceridemija i snižena koncentracija HDL-h, koje su najčešće prisutne kod pacijenata sa dijabetesnom neuropatijom, dodatno doprinose razvoju DS, amputaciji i mortalitetu. Poznato je da male, guste LDL čestice imaju važnu ulogu u razvoju kardiovaskularnih komplikacija u dijabetesu, ali je značaj ovih čestica kod pacijenata sa DS još uvek nedovoljno ispitan. U ovom radu ćemo razmotriti značaj određivanja standardnih i novih lipidnih biomarkera u cilju procene rizika za razvoj i progresiju DS.

Reference

American Diabetes Association. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44:S15-S33.

Stefanović A, Zeljković A, Vekić J, Spasojević-Kalimanovska V, Jelić-Ivanović Z, Spasić S. Dyslipidemia in type 2 diabetes mellitus. Archives of Pharmacy. 2019;69:338-348.

Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, Rand L, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986.

UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet. 1998;352(9131):837-853.

American Diabetes Association. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44:S151-S167.

Abbott CA, Carrington AL, Ashe H, Bath S, Every L, Griffiths J, et al. The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. Diabet Med. 2002;19(5):377– 384.

Kerr M, Barron E, Chadwick P, Evans T, Kong W, Rayman G, et al. The cost of diabetic foot ulcers and amputations to the National Health Service in England. Diabet Med. 2019;36(8):995-1002.

Vekic J, Zeljkovic A, Al Rasadi K, Cesur M, Silva-Nunes J, Stoian AP, et al. A new look at novel cardiovascular risk biomarkers: the role of atherogenic lipoproteins and innovative antidiabetic therapies. Metabolites. 2022;12(2):108.

Vekic J, Zeljkovic A, Stefanovic A, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V. Obesity and dyslipidemia. Metabolism. 2019;92:71-81.

Cai Z, Yang Y, Zhang J. A systematic review and meta-analysis of the serum lipid profile in prediction of diabetic neuropathy. Sci Rep. 2021;11(1):499.

Wiggin TD, Sullivan KA, Pop-Busui R, Amato A, Sima AA, Feldman EL. Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes. 2009;58(7):1634-40.

Callaghan BC, Feldman E, Liu J, Kerber K, Pop-Busui R, Moffet H, et al. Triglycerides and amputation risk in patients with diabetes: ten-year follow-up in the DISTANCE study. Diabetes Care. 2011;34(3):635-40.

Rizzo M, Kotur-Stevuljevic J, Berneis K, Spinas G, Rini GB, Jelic-Ivanovic Z, et al. Atherogenic dyslipidemia and oxidative stress: a new look. Transl Res. 2009;153(5)217-223.

Bolajoko EB, Mossanda KS, Adeniyi F, Akinosun O, Fasanmade A, Moropane M. Antioxidant and oxidative stress status in type 2 diabetes and diabetic foot ulcer. S Afr Med J. 2008;98(8):614-617.

Singh S, Sahay R, Krishna A. Oxidative stress in diabetic foot ulcer. Diabetes Metab Syndr. 2008;2(2):109-113.

Obermayer G. Oxidized low-density lipoprotein in inflammation-driven thrombosis. J Thromb Haemost. 2018;16(3):418-428.

Djekic S, Vekic J, Zeljkovic A, Stefanovic A, Kafedzic S, Zdravkovic M, et al. Investigation of IgG anti-oxLDL antibody levels and HDL and LDL subclasses in patients with ST-segment elevation acute myocardial infarction. Arch Med Sci. 2021. doi: 10.5114/aoms/135779

Vincent AM, Hayes JM, McLean LL, Vivekanandan-Giri A, Pennathur S, Feldman EL. Dyslipidemia-induced neuropathy in mice: the role of oxLDL/LOX-1. Diabetes. 2009;58(23):76-85.

Abd-Allha E, Hassan BB, Abduo M, Omar SA, Sliem H. Small dense low-density lipoprotein as a potential risk factor of nephropathy in type 2 diabetes mellitus. Indian J Endocrinol Metab. 2014;18(1):94-98.

Hirano T. Small dense LDL tied to diabetic retinopathy-similarity to atherosclerosis. J Atheroscler Thromb. doi: 10.5551/jat.ED174.

Willems D, Dorchy H, Dufrasne D. Serum antioxidant status and oxidized LDL in well-controlled young type 1 diabetic patients with and without subclinical complications. Atherosclerosis. 1998;137:S61-S64.

Rosales-Hernandez A, Cheung A, Podgorny P, Chan C, Toth C. Absence of clinical relationship between oxidized low density lipoproteins and diabetic peripheral neuropathy: a case control study. Lipids Health Dis. 2014;13:32.

Muhtaroğlu S, Barlak Keti D, Ünlühizarci K. Investigation of ischemia-modified albumin levels and some atherosclerosis-related serum parameters in patients with diabetic foot. Turk J Med Sci. 2016;46(1):126-32.

Mushtaq S, Khan S, Rashid MR. Study of glycated haemoglobin and lipid profile in patients with diabetic foot ulcer. Int J Contemp Med. 2020;7:F1-4.

Unlühizarci K, Muhtaroğlu S, Kabak S, Bayram F, Keleştimur F. Serum lipoprotein (a) levels in patients with diabetic foot lesions. Diabetes Res Clin Pract. 2006;71(2):119-23.

Gazzaruso C, Coppola A, Montalcini T, Baffero E, Garzaniti A, Pelissero G, et al. Lipoprotein(a) and homocysteine as genetic risk factors for vascular and neuropathic diabetic foot in type 2 diabetes mellitus. Endocrine. 2012;41(1):89-95.

McEneny J, Daniels JA, McGowan A, Gunness A, Moore K, Stevenson M, et al. A cross-sectional study demonstrating increased serum amyloid a related inflammation in high-density lipoproteins from subjects with type 1 diabetes mellitus and how this association was augmented by poor glycaemic control. J Diabetes Res. 2015;2015:351601.

Zeljkovic A, Vekic J, Mihajlovic M, Gojkovic T, Vladimirov S, Zeljkovic D, et al. Revealing the role of high-density lipoprotein in colorectal cancer. Int J Mol Sci. 2021;22(7):3352.

Jiang Y, Wang X, Xia L, Fu X, Xu Z, Ran X, et al. A cohort study of diabetic patients and diabetic foot ulceration patients in China. Wound Repair Regen. 2015;23(2):222-30.

Ikura K, Hanai K, Shinjyo T, Uchigata Y. HDL cholesterol as a predictor for the incidence of lower extremity amputation and wound-related death in patients with diabetic foot ulcers. Atherosclerosis. 2015;239(2):465-9.

Kotur-Stevuljević J, Vekić J, Stefanović A, Zeljković A, Ninić A, Ivanišević J, et al. Paraoxonase 1 and atherosclerosis-related diseases. Biofactors. 2020;46(2):193-205.

Lixandru D, Mohora M, Coman A, Stoian I, van Gils C, Aerts P, et al. Diet and paraoxonase 1 enzymatic activity in diabetic foot patients from Romania and Belgium: favorable association of high flavonoid dietary intake with arylesterase activity. Ann Nutr Metab. 2010;56(4):294-301.

Lotfollahi Z, Dawson J, Fitridge R, Bursill C. The anti-inflammatory and proangiogenic properties of high-density lipoproteins: an emerging role in diabetic wound healing. Adv Wound Care. 2021;10(7):370-380.

Tsatralis, T, Ridiandries A, Robertson S, Vanags L, Lam Y, Tan J, et al. Reconstituted high density lipoproteins promote wound repair and blood flow recovery in response to ischemia in aged mice. Lipids Health Dis. 2016;15(1):150.

Rizzo M, Berneis K, Zeljkovic A, Vekic J. Should we routinely measure low-density and high-density lipoprotein subclasses? Clin Lab. 2009;55(11-12):421-429.

Miljkovic M, Stefanovic A, Vekic J, Zeljkovic A, Gojkovic T, Simic-Ogrizovic S, et al. Activity of paraoxonase 1 (PON1) on HDL2 and HDL3 subclasses in renal disease. Clin Biochem. 2018;60:52-58.

Perovic Blagojevic I, Vekic J, Macut D, Ignjatovic S, Miljkovic-Trailovic M, Zeljkovic A, et al. Overweight and obesity in polycystic ovary syndrome: association with inflammation, oxidative stress and dyslipidaemia. Br J Nutr. 2021;13:1-9.

Objavljeno
2022/04/28
Broj časopisa
Vol. 72 Br. Notebook 2 (2022): Arhiv za farmaciju
Rubrika
Pregledni (Revijalni) rad
Autori koji objavljuju u ovom časopisu pristaju na sledeće uslove:

  1. Autori zadržavaju autorska prava i pružaju časopisu pravo prvog objavljivanja rada i licenciraju ga "Creative Commons Attribution licencom" koja omogućava drugima da dele rad, uz uslov navođenja autorstva i izvornog objavljivanja u ovom časopisu.

  2. Autori mogu izraditi zasebne, ugovorne aranžmane za neekskluzivnu distribuciju članka objavljenog u časopisu (npr. postavljanje u institucionalni repozitorijum ili objavljivanje u knjizi), uz navođenje da je članak izvorno objavljen u ovom časopisu.

  3. Autorima je dozvoljeno i podstiču se da postave objavljeni članak onlajn (npr. u institucionalni repozitorijum ili na svoju internet stranicu) pre ili tokom postupka prijave rukopisa, s obzirom da takav postupak može voditi produktivnoj razmeni ideja i ranijoj i većoj citiranosti objavljenog članka (Vidi Efekti otvorenog pristupa).